RCT Abstract - ENV-101 for the treatment of idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled phase 2 trial - Amsterdam 2025

ALERT 3: interstitial lung disease, pulmonary hypertension and intensive care unit

Chair(s): Elisabetta Renzoni, Sam Bayat, Bruno Crestani, Joanna Pepke-Zaba, Mathieu Marillier

Session type: Clinical trials session

RCT Abstract - ENV-101 for the treatment of idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled phase 2 trial

Toby M Maher

EVENTS HOME

Previous presentation

Next presentation

Session content

RCT Abstract - ENV-101 for the treatment of idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled phase 2 trial

Toby M Maher

Replay

Abstract

Slides

Late Breaking Abstract - Effect of nerandomilast on clinical outcomes in patients with idiopathic pulmonary fibrosis (IPF): data from final database lock of the FIBRONEER-IPF trial

Justin M Oldham

Replay

Abstract

Slides

Late Breaking Abstract - EFZO-FIT, the largest ever interventional trial in pulmonary sarcoidosis.

Daniel Culver

Replay

Abstract

Slides

Wrap-up by discussant and discussion

Bruno Crestani

Replay

Slides

Comparison of Guiding Sedation Level by Respiratory Effort Versus Usual Care in Mechanically Ventilated Patients: A Randomized Controlled Trial.

Touchapong Taksinwarajarn

Replay

Abstract

Slides

RCT Abstract - Efficacy and safety of sotatercept in patients with newly diagnosed pulmonary arterial hypertension at intermediate-to-high risk of mortality: Results from Phase 3 HYPERION study

Vallerie V. Mclaughlin

Replay

Abstract

Slides

Late Breaking Abstract - A randomized, double-blind, placebo-controlled study of treprostinil palmitil inhalation powder (TPIP) in patients with pulmonary arterial hypertension (PAH)

Ekkehard Grünig

Replay

Abstract

Slides

Wrap-up by discussant and discussion

Joanna Pepke-zaba

Replay

Slides

Session aims

The ALERT sessions (Abstracts Leading to Evolution in Respiratory Medicine Trials) showcase important and very late-breaking clinical trial data from all respiratory disease areas. Presenters, discussants, session chairs and the audience will actively discuss the showcased trials.

CDN Connection Issue

The ERS Congress 2025, Amsterdam

#{title}